Vimarsana
Biggest News Aggregation in the World

Page 3 - Insight Reports News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Insight Reports. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Insight Reports Today - Breaking & Trending Today

CENTOGENE Expands Multiomic Diagnostic Portfolio With - Vimarsana News

CENTOGENE Expands Multiomic Diagnostic Portfolio With

Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology...

CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference - Vimarsana News

CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 -- Centogene N.V. , the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today...

CENTOGENE Reports First Half 2023 Financial Results - Vimarsana News

CENTOGENE Reports First Half 2023 Financial Results

Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial PerformanceFirst half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth...

CENTOGENE Reports First Half 2023 Financial Results - Centogene (NASDAQ:CNTG) - Vimarsana News

CENTOGENE Reports First Half 2023 Financial Results - Centogene (NASDAQ:CNTG)

First half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue growth between 10%

CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients - Vimarsana News

CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients

Results from pivotal study published in Diagnostics journalConfirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher diseaseCould predict clinical course of patients and improve personalized care CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data confirming the

Source: yahoo.com